74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Intuitive Surgical Inc
Closed
SectorHealthcare
508.22 4.01
Overview
Share price change
24h
Min
487.19
Max
511.37
Income | 123M 688M |
|---|---|
Sales | 374M 2.4B |
P/E Sector Avg | 72.947 57.333 |
EPS | 2.21 |
Profit margin | 28.506 |
Employees | 15,638 |
EBITDA | 116M 810M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +21.36% upside |
Market Cap | -39B 168B |
|---|---|
Previous open | 504.21 |
Previous close | 508.22 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Intuitive Surgical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Intuitive Surgical Inc Forecast
Price Target
By TipRanks
21.36% upside
12 Months Forecast
Average 592.13 USD 21.36%
High 675 USD
Low 470 USD
Based on 18 Wall Street analysts offering 12 month price targets forIntuitive Surgical Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Intuitive Surgical Inc
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
